Therefore, peripherally restricted CB1R antagonists may be good candidates for slowing CKD progression, especially during metabolic nephropathies, and experimental data are encouraging to move up forward clinical trials in the short term. The gene discussed is CNR1; the disease is chronic kidney disease.